The use of trastuzumab in HER2 positive disease has also increased since the mid-2000s, and our results indicate that women with HER2 positive disease had lower breast cancer mortality than those with HER2 negative disease after adjustment for other factors, probably owing to the use of trastuzumab. Here, ERBB2 is linked to breast carcinoma.